Chardan Capital has raised its target price by $ 5 on Viking Therapeutics, Inc. (NASDAQ:VKTX) to $ 20.00 from the previous mark of $ 15.00, suggesting the upside potential of more than 192.83 percent from the existing levels. However, the brokerage has maintained its Buy rating on the stock, Benzinga reported.
Shares of Viking Therapeutics, Inc. traded low $ -0.05 or -0.73 percent on Monday, reaching $ 6.78 with volume of 966.90 thousand shares. The stock opened positive for the day at $ 6.98, after closing the previous day trading at $ 6.83. According to the previous trading day, closing price of $ 6.83, representing a 109.51 % increase from the 52 week low of $ 3.26 and a 23 % decrease over the 52 week high of $ 8.87.
With respect to the key metrics, Viking Therapeutics, Inc. stock has advanced $ 0.26 or 4.00 percent, reaching $ 6.52 during the simple moving average (SMA) period of 200 days. Similarly, the stock has decreased $ -0.53 or -7.00 percent, before arriving at $ 7.31 during the SMA50-day period.
Moving ahead, the analysts surveyed by Thomson Reuters are predicting, Viking Therapeutics, Inc. to report 3Q20 loss of $ 0.15 per share from revenue of $ 0.00 million. For the full year, analysts anticipate top line of $ 0.00 million, while looking forward to loss of $ 0.59 per share bottom line.
Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. Its lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta, which is in Phase II clinical trials to treat patients with non-alcoholic fatty liver disease and elevated low-density lipoprotein cholesterol. The companys lead drug candidate also includes VK5211, an orally available non-steroidal selective androgen receptor modulator that is in Phase II clinical trials for the treatment of patients recovering from non-elective hip fracture surgery.
